---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-037916"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T10:37:40.691405+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Q3 2023: Total revenue $55M (-17% YoY); Cell Engineering up 51%; revises FY23 outlook

## Summary
- Cell Engineering revenue $37M (+51% YoY); Biosecurity revenue $18M with 62% gross margin.
- Loss from ops $(286)M including $96M impairment charge; Adj. EBITDA $(84)M vs $(72)M prior year.
- Added 21 new Cell Programs in Q3, 40% growth YoY; full-year target revised to 80-85 programs.
- New partnerships: Pfizer RNA drug discovery (up to $331M milestones) and Google Cloud AI deal.
- FY23 revenue guidance cut to $250-260M; Cell Engineering $145-150M; Biosecurity up to $110M.

## SEC filing metadata
- accession: 0001628280-23-037916
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000162828023037916/0001628280-23-037916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000162828023037916/dna-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-037916
- JSON: https://secwatch.observer/filing/0001628280-23-037916.json
- Plain text: https://secwatch.observer/filing/0001628280-23-037916.txt

## Key facts
- Earnings Releases
  Ginkgo Bioworks Holdings, Inc. reported third quarter ended September 30, 2023 results: revenue $55 million, net income $(286) million. Guidance lowered.
  - Period: third quarter ended September 30, 2023
  - Revenue: $55 million
  - Net income: $(286) million
  - Guidance: lowered
  - Result: reported results
  source text: of next-generation biological intelligence capabilities, including AI-based epidemic forecasting Third Quarter 2023 Financial Highlights • Third quarter 2023 Total revenue of $55 million, down from $66 million in the comparable prior year period, a decrease of 17% primarily driven by the expected ramp down of K-12 testing in Ginkgo’s Biosecurity segment • Third
  evidence_url: https://www.sec.gov/Archives/edgar/data/1830214/000162828023037916/0001628280-23-037916-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.